– July 1, 2011
July 1, 2011
View Archives Issues
-
Improving Survival Rates by Surgical Resection of Colorectal Liver Metastases
In a retrospective analysis of aggressive two-stage hepatic resection of colorectal metastases, survival was 51% at 5 years compared to only 15% for comparable patients treated with chemotherapy alone. The complexity of the surgical approach and the advent of potentially more effective systemic therapies highlight the need for a definitive randomized trial before such an approach is assimilated into community practice. -
Colorectal Adjuvant Chemotherapy: Timing Is Something
In a retrospective review, delay beyond 60 days in initiating adjuvant chemotherapy after surgery for colorectal cancer was associated with poorer overall survival. Although factors such as surgical complications or the existence of comorbidities may explain the delays for some of the cases, other "administrative" factors, such as delays resulting from insurance authorizations or referral setbacks, are to be avoided, if at all possible. -
CML Treatment in the Elderly: Imatinib Levels the Playing Field
Older age is an adverse prognostic factor for chronic myeloid leukemia (CML) in the pre-tyrosine kinase era. The authors evaluated the influence of age on outcomes among 559 chronic-phase CML patients treated with imatinib. -
Population Screening for the Early ID of Prostate Cancer
To assess whether screening for prostate cancer reduces prostate-specific mortality, a population-based, randomized, controlled trial for a random sample of men between the ages of 50 to 69 in a single city were screened every third year from 1987 to 1996. There was no significant difference in the rate of death from prostate cancer for the screened group compared to the control group after 20 years of follow-up. -
Extranodal Marginal Zone Lymphoma
The term marginal-zone lymphoma (MZL) refers to three distinct but closely related lymphoprolferative disorders: mucosa-associated lymphoid tissue (MALT) lymphoma (extranodal MZL), splenic MZL, and nodal MZL. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.